ROZLYTREK Coverage
Benefits Investigations
Genentech BioOncology® Access Solutions for ROZLYTREK can conduct a
benefits investigation (BI) to help you determine if a Genentech
medicine is covered, if prior authorizations (PAs) are required, which
specialty pharmacy (SP) the health insurance plan prefers and if
patient assistance might be needed.
Potential outcomes of a BI:
- Treatment is covered
- PA is required
- Treatment is denied
Both the Prescriber Service Form and the Patient Consent Form must
be received before Genentech BioOncology Access Solutions can begin
helping your patient.
These can be downloaded from Forms and Documents or submitted online via My Patient Solutions.
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
Prior Authorization
Genentech BioOncology® Access Solutions for ROZLYTREK can help you
identify if a prior authorization (PA) is necessary and offer
resources as you obtain it for your patient. Both the Prescriber
Service Form and the Patient Consent Form must be received before
Genentech BioOncology Access Solutions can begin helping your
patient.
If your patient’s request for a PA is not granted, your BioOncology Field Reimbursement Manager (BFRM) or Genentech BioOncology Access Solutions Specialist can work with you to determine your next steps. You can find more tips like this in Forms and Documents.
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
SureStart® Program
With the SureStart Program, eligible patients taking ROZLYTREK may receive free medicine while awaiting an insurance coverage determination.
If you think your patient qualifies for the SureStart Program,
submit the completed Prescriber Service Form and the Patient Consent
Form to Genentech BioOncology® Access Solutions for ROZLYTREK.
Eligible patients can receive a 30-day supply of ROZLYTREK. Once coverage has been determined, the patient no longer qualifies for the SureStart Program.
